DNA甲基化与1型糖尿病中两种神经病变表型28年发病率:匹兹堡糖尿病并发症流行病学队列研究
在匹兹堡糖尿病并发症流行病学(EDC)研究的儿童期起病1型糖尿病队列中,对基线无糖尿病周围神经病变(DPN)的282人和无神经病理性疼痛(NP)的365人进行DNA甲基化(EPIC阵列)前瞻性分析,随访28年。发现3个CpG位点甲基化程度较高与DPN风险降低显著相关(FDR≤0.05),未发现单个CpG与NP显著相关,但识别出49个NP相关差异甲基化区域。
要点
- 在282名基线无DPN的1型糖尿病患者中,随访28年有154人(54.6%)发生DPN。
- cg06163904(CHMP6)、cg10835127(CACNA1B)和cg18945945(PKNOX1)三个CpG位点甲基化程度较高与DPN风险降低显著相关(FDR≤0.05)。
- 未发现单个CpG与NP显著相关,但识别出49个NP相关差异甲基化区域。
核心结论
- 研究在多个生物学合理位点发现DNA甲基化与28年DPN和NP发病率之间的关联。
- 最值得注意的是,发现了PKNOX1的DNA甲基化与未来DPN之间的新关联,包括PKNOX1甲基化的遗传影响证据,并在一个外部糖尿病队列中得到验证。
- PKNOX1此前已被认为与药物诱导的神经病变有关;本研究结果提供了有力证据,表明PKNOX1的表观遗传调控也可能在糖尿病神经病变的发展中发挥功能作用。
- 作者认为,所识别位点的表观遗传修饰值得进一步研究,以为DPN的预防提供潜在靶点。
研究设计与样本
- 研究为匹兹堡糖尿病并发症流行病学(EDC)研究中的前瞻性表观基因组关联研究(EWAS),对象为儿童期起病(<17岁)的1型糖尿病患者。
- DPN定义为以下标准中满足两项或以上:与DPN一致的状;腱反射减弱;或感觉检查异常。
- NP定义为在EDC检查期间或密歇根神经病变筛查量表(MNSI)上报告的足部烧灼痛、酸痛或刺痛。
- 分析基线为1988—1998年间采集的首份可用血源性DNA标本的时间(平均年龄27岁;糖尿病病程19年)。
- 经质量控制后,在683,597个CpG位点上使用EPIC阵列进行DNA甲基化分析,采用Cox模型分别分析282名基线无DPN个体的DPN发生时间和365名基线无NP个体的NP发生时间。
主要发现
- 在28年随访期间,154人(54.6%)发生DPN,148人(40.5%)发生NP。
- 三个CpG位点甲基化程度较高与DPN风险降低显著相关(FDR≤0.05):cg06163904(CHMP6)、cg10835127(CACNA1B)和cg18945945(PKNOX1)。
- 在调整临床危险因素后,CpG与DPN的关联保持相似。
- 在PKNOX1区域为cg18945945识别出75个甲基化数量性状基因座(meQTL),其中59个在一个外部糖尿病队列中得到验证。
- 单样本孟德尔随机化(MR)为cg18945945与DPN之间可能存在的因果关联提供了名义证据(p=0.01)。
关键数值与推荐
- FDR<0.05视为统计学显著。
- DPN定义:以下标准中满足两项或以上:与DPN一致的症状;腱反射减弱;或感觉检查异常。
- NP定义:在EDC检查期间或MNSI上报告的足部烧灼痛、酸痛或刺痛。
- 分析基线:1988—1998年间采集的首份可用血源性DNA标本的时间(平均年龄27岁;糖尿病病程19年)。
- DNA甲基化分析覆盖683,597个CpG位点(EPIC阵列)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetic peripheral neuropathy (DPN) and neuropathic pain (NP) are common complications of type 1 diabetes that can greatly affect quality of life. Studying DNA methylation (DNAm) may help identify potential therapeutic targets; however, epigenome-wide association studies (EWAS) of DPN and NP are lacking. We thus performed prospective EWAS of 28 year DPN and NP incidence in the Pittsburgh Epidemiology of Diabetes Complications (EDC) study of childhood-onset (<17 years) type 1 diabetes. METHODS: DPN was defined as two or more of the following criteria: symptoms consistent with DPN; decreased tendon reflexes; or abnormal sensory examination. NP was reported as burning, aching or stabbing pain in the feet during an EDC examination or on the Michigan Neuropathy Screening Instrument (MNSI). The time of the first available blood-derived DNA specimen collected between 1988-1998 was considered the analytic 'baseline' (mean age 27 years; diabetes duration 19 years). After quality control, DNAm (EPIC array) at 683,597 CpGs was analysed in Cox models for time-to-DPN in 282 individuals free of DPN at baseline and time to NP in 365 individuals free of NP at baseline. False discovery rate (FDR) <0.05 was considered statistically significant. We also identified differentially methylated regions (DMRs), functional interaction networks and genetic variants associated with DNAm (methylation quantitative trait loci [meQTLs]), and performed Mendelian randomisation (MR) to assess evidence of causality. RESULTS: Over 28 years, 154 individuals (54.6%) developed DPN and 148 (40.5%) developed NP. Greater methylation at three CpGs was significantly associated (FDR≤0.05) with reduced hazard of DPN: cg06163904 (CHMP6); cg10835127 (CACNA1B); and cg18945945 (PKNOX1). CpG associations with DPN remained similar after adjustment for clinical risk factors. We identified 75 meQTLs for cg18945945 in the PKNOX1 region, 59 of which were validated in an external diabetes cohort. One-sample MR provided nominal evidence for a potentially causal association between cg18945945 and DPN (p=0.01). While no individual CpGs were significantly associated with NP, there were 49 NP-associated DMRs. CONCLUSIONS/INTERPRETATION: Our study identified associations between DNAm and 28 year incidence of DPN and NP at several biologically plausible loci. Most notably, we identified a novel association between DNAm of PKNOX1 and future DPN, including evidence of a genetic influence on PKNOX1 methylation that was validated in an external diabetes cohort. PKNOX1 has previously been implicated in drug-induced neuropathy; our results provide strong evidence that epigenetic regulation of PKNOX1 may also play a functional role in the development of diabetic neuropathy. Our results suggest that epigenetic modification of the identified loci warrants further study to inform potential targets for prevention of DPN.
引用
- Zhou J, Mychaleckyj JC, Onengut-Gumuscu S, et al. DNA methylation and 28 year incidence of two neuropathy phenotypes in type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications cohort study. Diabetologia. 2025. PMID: 40266295. doi:10.1007/s00125-025-06427-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。